Zymeworks Inc. Common Stock (ZYME)

About ZYME

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists o…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

231

Website

www.zymeworks.com

Fundamentals

1-day range

$24.89$25.73

Market cap

$1.59B

P/E (trailing)

—

P/E (forward)

21.35

EPS (trailing)

$-2.02

Dividend yield

—

Beta

1.15

Avg. volume

598.6K

Forecasts

12 analyst ratings

Zymeworks Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ZYME

  Zymeworks Inc. Common Stock

  $28.27

  ▼ 2.55%
  Market cap $1.59BP/E —
  $13.48$29.75
• TRAX

  First Tracks Biotherapeutics Inc. Ordinary Shares

  $41.77

  ▼ 6.64%
  Market cap $1.61BP/E —
  $14.72$49.91
• AAPG

  Ascentage Pharma Group International American Depository Shares

  $18.28

  ▼ 2.16%
  Market cap $1.57BP/E —
  $30$91.5
• INVA

  Innoviva Inc. Common Stock

  $20.97

  ▲ 0.05%
  Market cap $1.53BP/E 4.21
  $16.52$25.15
• MRVI

  Maravai LifeSciences Holdings Inc. Class A Common Stock

  $7.67

  ▼ 8.42%
  Market cap $1.66BP/E —
  $2.28$9.42
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.51BP/E 14.51
  $28.25$60.08
• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.69BP/E —
  $10.3$30.99

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44
  Benzinga · 8/10/2026
• Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40
  Benzinga · 8/7/2026
• Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
  Benzinga · 8/7/2026
• HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51
  Benzinga · 8/5/2026
• A Post Acquisition Look At Zymeworks
  SeekingAlpha · 8/5/2026

• Mark Hollywood · July 6, 2026 · Grant

  939 @ $22.22
• Schneider Paul R · May 13, 2026 · Grant

  119.0K
• Schneider Paul R · May 13, 2026 · Grant

  178.0K
• Schayowitz Adam · April 9, 2026 · Grant

  76.0K
• Schayowitz Adam · April 9, 2026 · Grant

  47.0K
• Schayowitz Adam · April 9, 2026 · Grant

  70.0K
• Platshon Scott · April 9, 2026 · Grant

  76.0K
• Platshon Scott · April 9, 2026 · Grant

  47.0K
• Platshon Scott · April 9, 2026 · Grant

  70.0K
• Stafford Kristin · April 6, 2026 · Grant

  50.0K
• Stafford Kristin · April 6, 2026 · Grant

  119.0K
• Stafford Kristin · April 6, 2026 · Grant

  178.0K

Institutional Ownership

March 31, 2026

Total shares held

70.02M

Total value held

$1.74B

Institutional holders

207